Clinical trial
Clinical Study to Evaluate the Safety and Feasibility of Targeting CD269 Chimeric Antigen Receptor Engineered T Cell (spCART-269) Injection in the Treatment of CD269-positive Multiple Myeloma
NCT04500431 is registered in ClinicalTrials.gov with Shanghai Tongji Hospital, Tongji University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Study to Evaluate the Safety and Feasibility of Targeting CD269 Chimeric Antigen Receptor Engineered T Cell (spCART-269) Injection in the Treatment of CD269-positive Multiple Myeloma
- Lead sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- July 1, 2018
- Completion date
- December 1, 2022
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.